Cleveland BioLabs, Inc.
If you purchased Cleveland BioLabs, Inc. securities and would like to join the action, please click "Join This Action" below.
CLEVELAND BIOLABS MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF CLEVELAND BIOLABS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – CBLI
October 20, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Cytocom, Inc. is fair to Cleveland BioLabs shareholders. On behalf of Cleveland BioLabs shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
According to the press release announcing the proposed merger, Cytocom shareholders will have a majority position in the newly combined entity. The investigation concerns whether Cleveland BioLabs and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible consideration for Cleveland BioLabs shareholders; and (2) disclose all material information necessary for Cleveland BioLabs shareholders to adequately assess and value the proposed transaction.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.